4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why

4D Molecular Therapeutics FDMT announced interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease. 

The aerosol delivery procedure for 4D-710 was well tolerated. One patient experienced mild dry throat and fatigue during aerosol delivery.

Following aerosol administration, 4D-710 was well tolerated in all 3 participants (9-12 months follow-up) with no 4D-710-related adverse events, dose-limiting toxicities, or serious adverse events.

Biomarker analyses demonstrated widespread and consistent CFTR expression throughout all lung biopsy samples.

Percent predicted forced expiratory volume in one second (ppFEV1) meaningfully improved in participants with moderate ppFEV1 impairment at baseline.

ppFEV1 was maintained stably in participants with normal or mild impairment at baseline.

Bronchoscopy sample results demonstrated widespread and consistent expression of the cystic fibrosis transmembrane conductance regulator (CFTR) transgene protein in 92-99% of lung airway cells at levels significantly above normal control lung tissues.

"This evidence of tolerability, high level CFTR protein expression and early clinical activity in three participants is promising for the ongoing development of this aerosolized product candidate for cystic fibrosis lung disease."

Recently, the company released interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM trial for wet age-related macular degeneration. 

Price Action: FDMT shares are up 9.47% at $20.00 during the premarket session on the last check Thursday.